Management

Chronic Myeloid Leukemia (CML)

1. Definition & Pathophysiology

• Myeloproliferative disorder defined by t(9;22) → Philadelphia chromosome (Ph+) → BCR::ABL1 fusion gene
• Present in >95% of CML cases
• BCR::ABL1 = constitutively active tyrosine kinase → cytokine-independent proliferation + blocked apoptosis
• Most common fusion protein: p210 (CML); p190 (Ph+ ALL); p230 (rare, neutrophilic CML)
• Ph chromosome present in: all myeloid lineages + B-cells + small proportion of T-cells (originates in hematopoietic stem cell)

2. Epidemiology & Presentation

• More common in adults (not children)
• Classic labs: markedly elevated WBC (can exceed 300×10⁹/L), normal or elevated platelets, variable Hgb
• Thrombocytopenia is NOT a routine finding at diagnosis
• Basophilia is universal; eosinophilia in ~90% of cases
• Symptoms: fatigue, night sweats, weight loss, early satiety, splenomegaly
• Hyperleukocytosis → leukostasis → CNS symptoms (headache, stroke-like) → treat with hydroxyurea + allopurinol ± leukapheresis

3. Phases of CML

• AP cytogenetics: trisomy 8, isochromosome 20q in addition to t(9;22)

4. Risk Scoring Systems

Memory Hook: Sokal = Spleen, Blasts, Age, Platelets only — Hasford adds Basophils + Eosinophils

5. Treatment Response Milestones (ELN 2020)

• CCyR (complete cytogenetic response) = gold standard at 12 months
• MMR (major molecular response) = BCR-ABL ≤0.1%
• Warning at 3 months → continue TKI, reassess at 6 months; do NOT switch yet
• Failure at any milestone → BCR::ABL1 mutational analysis before switching

6. First-Line TKI Selection

By Risk (ELTS Score)

• Low-risk CP-CML: Imatinib, dasatinib, nilotinib, or bosutinib — all acceptable
• Intermediate/High-risk CP-CML: 2nd-gen TKI preferred (Category 1) — dasatinib, nilotinib, bosutinib
  • Imatinib acceptable but not Category 1 for intermediate/high risk
  • 2nd-gen TKIs → faster and deeper molecular responses

By Comorbidity

7. TKI Administration Rules

Nilotinib is the ONLY TKI dosed twice daily

8. TKI Toxicity Profiles

9. Adherence

• Most important factor in treatment success
• ADAGIO trial: adherence ≤85% → 27% probability of losing CCyR within 2 years vs. only 1.5% with >85% adherence
• Nearly 30% of CML patients are non-adherent

10. Second-Line & Beyond

TKI Sequencing Rules

• Failed 1st-gen TKI (imatinib) → switch to 2nd-gen TKI (dasatinib, nilotinib, bosutinib)
• Failed 2nd-gen TKI in 1st line → switch to alternate 2nd-gen TKI
• Do NOT switch from 2nd-gen TKI → imatinib
• Failed ≥2 TKIs → asciminib (STAMP inhibitor) or ponatinib
• Increasing TKI dose to BID = not supported by evidence in CP-CML

11. T315I "Gatekeeper" Mutation

• Occurs in ~15% of imatinib-resistant patients
• Confers resistance to ALL 1st- and 2nd-gen TKIs (imatinib, dasatinib, nilotinib, bosutinib)
• Treatment of choice: Ponatinib (3rd-gen TKI)
• Alternative: Omacetaxine (acts independently of BCR-ABL binding)
• Ultimate option: Allogeneic HSCT (especially if TKI options exhausted)

12. Advanced Phase Management

Accelerated Phase (AP)

• Goal: induce back to second chronic phase → allo-HSCT
• Preferred after failing ≥2 TKIs: Omacetaxine (protein synthesis inhibitor — BCR-ABL independent)
• Ponatinib for AP only if T315I mutation present

Blast Crisis (BP)

• Treatment of choice: Allogeneic HSCT
• Bridge to transplant: Dasatinib 140 mg daily or Ponatinib
• TKI + high-dose chemotherapy before transplant improves outcomes

Autologous HSCT has NO role in any phase of CML

13. Treatment-Free Remission (TFR)

Criteria for TKI discontinuation:

• Chronic phase only (no prior AP/BP)
• TKI therapy ≥3–5 years
• Stable deep molecular response (MR4 or better, BCR-ABL ≤0.01%) for ≥2 years
• Strict monitoring required after discontinuation

TFR requires MR4, NOT just MMR (≤0.1%)

14. Imatinib — Additional Targets

Inhibits: BCR-ABL1 + c-KIT + PDGFR (platelet-derived growth factor receptor) → Also used in GIST and other malignancies where these are overexpressed

15. Mechanism of Imatinib

• Binds ATP-binding pocket of BCR-ABL1 kinase
• Acts as synthetic ATP mimic → displaces ATP → blocks/inhibits phosphorylation of downstream effectors
• Result: dephosphorylation of downstream targets → blocked proliferation signal

16. Special Situations

• CML in pregnancy: All TKIs contraindicated → Interferon alfa (safe)
  • Interferon: 3 million units/m² 5×/week; ~70% 10-year survival (low Sokal)
  • Toxicities: fatigue, low-grade fever, weight loss, elevated LFTs, neuropsychiatric symptoms
• Sorafenib/Sunitinib: do NOT inhibit BCR-ABL → not effective in CML
• Rituximab: no role in CML (used in CLL/NHL)

Quick Review

A. PK is a 65-year-old female with a history of chronic obstructive pulmonary disease, psoriasis and seasonal allergies. She presented for a physical examination as required by her new insurance plan, where her blood work was remarkable for a white blood cell count (WBC) of 94,000 cells/mm³, platelets of 197,000 cells/mm³ and a hemoglobin of 13.1 g/dL. Her serum chemistries were all within normal limits. She has been referred to a hematologist for further workup. PK is examined by the hematologist and consents to a bone marrow biopsy. The biopsy is notable for marked hypercellularity. Cytogenetic analysis is positive for t(9;22), confirming the diagnosis of chronic phase CML. She is considered to have intermediate-risk disease according to her ELTS score.

Given this information, which of the following is the most appropriate initial therapy for PK?

• A. Imatinib
• B. Bosutinib
• C. Ponatinib
• D. Dasatinib

[expand] The most appropriate initial therapy for PK is B. Bosutinib.

Rationale for Selection

The choice of a tyrosine kinase inhibitor (TKI) for a newly diagnosed patient with Chronic Myeloid Leukemia (CML) is based on risk stratification and the patient’s specific comorbidities.

1. Risk Stratification (ELTS Score): PK has intermediate-risk, chronic phase CML according to her ELTS score. For patients in the intermediate- or high-risk groups, the NCCN Guidelines® provide a Category 1 recommendation for the second-generation TKIs bosutinib, dasatinib, or nilotinib.
2. Superiority of Second-Generation TKIs: Data from randomized trials demonstrate that second-generation TKIs like bosutinib are associated with superior cytogenetic and molecular response rates and lower rates of disease progression when compared to imatinib. While imatinib is an acceptable option, it is not a Category 1 choice for intermediate-risk disease in these guidelines.
3. Impact of Comorbidities (COPD): PK has a history of chronic obstructive pulmonary disease (COPD). This is the deciding factor in her case. According to the sources, bosutinib is more appropriate than dasatinib for a patient with pulmonary disease.
4. Avoidance of Dasatinib: Dasatinib is associated with a risk of pleural effusions and pulmonary arterial hypertension. Patients with underlying pulmonary disease, such as COPD, are at higher risk for these complications, making dasatinib a less appropriate choice for PK.

Why Other Options are Inappropriate

• Imatinib (Option A): While it is a recommended treatment option, it is not considered a Category 1 recommendation for intermediate-risk disease because second-generation agents achieve faster and deeper responses.
• Ponatinib (Option C): This third-generation TKI is generally reserved for the third-line setting (after failure of at least two prior TKIs) or for patients who harbor the specific T315I mutation.
• Dasatinib (Option D): As noted above, the risk of pleural effusions makes it less desirable for a patient with a history of COPD.

[/expand]

B. PK is started on bosutinib 400 mg PO daily. After 12 months of therapy, she has not achieved a complete cytogenetic response. Drug interactions and non-adherence with therapy have been ruled out.

What is the most appropriate intervention for PK at this point in time?

• A. Increase bosutinib to twice daily
• B. Change to high-dose imatinib
• C. Order BCR::ABL mutational analysis
• D. Change to asciminib

[expand]Correct answer = C (Order BCR::ABL mutational analysis)

The most appropriate intervention for PK at this point is C. Order BCR::ABL mutational analysis.

Rationale for Mutational Analysis

• Failure to Meet Milestones: Achievement of a complete cytogenetic response (CCyR) within 12 months is considered the "gold standard" for patients with chronic phase CML (CP-CML) because it is strongly associated with improved survival. PK has failed to achieve this milestone, which classifies her response as TKI-resistant disease (falling into the "Red" or "Failure" category in consensus guidelines).
• Guideline Recommendation: Current recommendations state that BCR::ABL kinase domain mutational analysis should be performed for CP-CML patients who have an inadequate initial response, which is defined as failing to achieve establish response milestones.
• Guiding Therapy: Identifying a specific mutation is critical because different point mutations predict resistance to certain TKIs and sensitivity to others. For example, the T315I mutation would render all first- and second-generation TKIs (including bosutinib) ineffective, necessitating a switch to agents like ponatinib or asciminib.

Why Other Options Are Inappropriate

• Option A (Increase bosutinib to twice daily): There is no clinical evidence that increasing the dose of a second-generation TKI like bosutinib to twice-daily dosing provides an improved response in patients with chronic phase disease.
• Option B (Change to high-dose imatinib): If a second-generation TKI is used in the first-line setting, the patient should be switched to an alternate second-generation or third-generation TKI; it is inappropriate to switch "backward" to the first-generation TKI imatinib. Furthermore, dose escalation of imatinib is unlikely to benefit patients who never achieved a cytogenetic response with a standard dose.
• Option D (Change to asciminib): Asciminib is currently indicated for patients with CP-CML who have been previously treated with two or more TKIs or for those who harbor the T315I mutation. Since PK has only failed one TKI and her mutational status is unknown, mutational testing must precede the choice of a third-generation agent.

[/expand]

C. Which of the following counseling points regarding any TKI therapy for CML would be most important to stress to PK during your discussions with her?

• A. Food does not impact the effectiveness of TKIs.
• B. She can miss one dose of TKI per week without a difference in treatment outcome.
• C. TKIs should be taken once daily to maintain serum steady state concentration.
• D. TKIs may be discontinued if MMR is sustained for 2 years.

[expand]The most important counseling point to stress to PK from the provided options is D. TKIs may be discontinued if MMR is sustained for 2 years.

According to the sources, this is the correct answer for this patient case. The rationale for this selection, and the reasons why the other options are incorrect, are as follows:

Rationale for the Correct Answer (Option D)

• Treatment-Free Remission (TFR): Advances in TKI therapy have allowed CML to be managed as a chronic disease, with the ultimate goal for many patients being the cessation of therapy.
• Discontinuation Criteria: Outside of a clinical trial, patients may consider stopping their TKI if they meet specific criteria: being at least 18 years old, having no history of advanced-phase disease, taking a TKI for at least 3–5 years, and maintaining a stable deep molecular response (MR4 or better) for at least 2 years.
• Counseling Nuance: While clinical criteria specifically require a stable MR4 (BCR::ABL1 ≤ 0.01%), the case answer key recognizes Option D as the most appropriate counseling point among the choices provided to describe the possibility of TFR.

Why the Other Options are Incorrect

• Option A (Food): This is incorrect because food has a significant impact on several TKIs. Nilotinib must be taken on an empty stomach because food can dangerously increase its absorption. Conversely, bosutinib and imatinib should be taken with food and a large glass of water to improve tolerability.
• Option B (Missing Doses): This is false and dangerous. Adherence is the most important factor contributing to treatment success and preventing relapse. Patients with an adherence rate ≤ 85% have a 27% probability of losing their complete cytogenetic response within two years, compared to only 1.5% for those with > 85% adherence.
• Option C (Once Daily Dosing): This is incorrect because not all TKIs follow a once-daily schedule. While imatinib, dasatinib, bosutinib, and ponatinib are taken once daily, nilotinib must be taken twice daily.

[/expand]

VM is a 46-year-old male who was diagnosed with Philadelphia chromosome positive CP-CML four years ago. He does not have any genetic mutations. He was initially started on imatinib, but was changed to dasatinib when he did not achieve a complete cytogenetic response after 12 months. He developed a pleural effusion while taking dasatinib and is unable to take nilotinib due to a major drug interaction with his concurrent medications. After being off therapy for the past four months, his most recent bloodwork revealed t(9;22) as well as trisomy 8 and isochromosome 20q, confirming the conversion to accelerated phase.

What is the most appropriate therapy for VM at this point in time?

• A. Interferon alfa
• B. Omacetaxine
• C. Ponatinib
• D. Allogeneic stem cell transplantation
• E. Autologous stem cell transplantation

[expand] The most appropriate therapy for VM at this point in time is B. Omacetaxine.

Rationale for Omacetaxine (Option B)

• Treatment History: VM has either failed or is unable to tolerate three tyrosine kinase inhibitors (TKIs): imatinib (failure to achieve CCyR), dasatinib (intolerance due to pleural effusion), and nilotinib (contraindicated due to major drug interactions).
• Indication for AP-CML: Omacetaxine is recommended as a treatment option for patients who experience disease progression to accelerated phase (AP-CML) due to resistance or intolerance to two or more TKIs.
• Mechanism of Action: Because its antileukemic effect is independent of BCR::ABL binding (acting as a reversible ribosomal protein synthesis inhibitor), it remains active in patients resistant to multiple TKI therapies.
• Clinical Goal: The primary goal of therapy in the accelerated phase is to induce the patient back into a second chronic phase.

Why Other Options are Inappropriate

• A. Interferon alfa: This is a historical treatment with no standard role in current practice, except specifically for the treatment of CML during pregnancy.
• C. Ponatinib: While ponatinib is a treatment option for patients resistant to multiple TKIs, some guidelines specifically state it is not recommended for AP-CML unless the patient harbors the T315I mutation, which VM does not have
• D. Allogeneic stem cell transplantation: While allogeneic HSCT should be considered for patients in the advanced phase, it is generally pursued after the patient is induced back into a second chronic phase using TKI therapy or omacetaxine. Using TKIs or omacetaxine to reduce disease burden prior to transplant is associated with better outcomes.
• E. Autologous stem cell transplantation: There are currently no recommendations for autologous HSCT in any phase of CML management.

Pharmacist Clinical Note

For the BCOP exam, note that while bosutinib or ponatinib could also be considered for AP-CML, omacetaxine is a specific preferred choice when a patient has progressed to the accelerated phase after failing multiple TKIs. Additionally, omacetaxine requires frequent monitoring for its major adverse effect, myelosuppression, and caution in patients with diabetes due to the risk of hyperglycemia.

[/expand]

A. LP is a 42-year-old female who has always enjoyed excellent health. She takes no medications other than an over-the-counter NSAID for sporadic migraine headaches. She presented for a physical examination as required by her new insurance plan, where her blood work was remarkable for a WBC of 94,000 cells/mm³, platelets of 197,000 cells/mm³ and a hemoglobin of 13.1 g/dL. Her serum chemistries were all within normal limits. She has been referred to a hematologist for further workup. LP is examined by the hematologist and consents to a bone marrow biopsy. The biopsy is notable for marked hypercellularity. Cytogenetic analysis is positive for t(9;22), confirming the diagnosis of chronic phase CML. She is considered to have intermediate-risk disease according to her ELTS score.

Which of the following is the most appropriate initial therapy for LP?

• A. Imatinib
• B. Bosutinib
• C. Ponatinib
• D. Allogeneic stem cell transplant

[expand] The most appropriate initial therapy for LP is B. Bosutinib.

Rationale for Therapy Selection

According to the provided sources, the selection of a tyrosine kinase inhibitor (TKI) for a newly diagnosed patient with Chronic Myeloid Leukemia (CML) is guided by their risk stratification and comorbidities:

• Intermediate-Risk Status: LP has intermediate-risk, chronic phase CML (CP-CML) based on her ELTS score. For patients in the intermediate- or high-risk groups, the NCCN Guidelines provide a Category 1 recommendation for the second-generation TKIs bosutinib, dasatinib, or nilotinib.
• Superiority of Second-Generation TKIs: Randomized trials have demonstrated that second-generation TKIs like bosutinib are associated with superior cytogenetic and molecular response rates at specific time points and lower rates of disease progression compared to imatinib.
• Younger Patient Considerations: For younger women, second-generation TKIs may be preferred to achieve a fast, deep molecular response, which is a prerequisite for potentially discontinuing therapy later for reasons such as family planning.

Why Other Options Are Less Appropriate

• A. Imatinib: While imatinib is a recommended treatment option, it is not considered a Category 1 recommendation for patients with intermediate-risk disease.
• C. Ponatinib: This third-generation TKI is reserved for patients who have failed at least two prior TKIs or those who harbor the T315I mutation.
• D. Allogeneic stem cell transplant: This is generally considered a second- or third-line intervention, or used for patients with advanced-phase disease (accelerated phase or blast crisis).

[/expand]

B. LP is started on bosutinib 400 mg PO daily. After 12 months of therapy, she has not achieved a complete cytogenetic response. Drug interactions and non-adherence with therapy have been ruled out. What is most appropriate second-line treatment of chronic phase disease for LP at this point in time?

• A. Increase bosutinib to twice daily
• B. Change to high-dose imatinib
• C. Change to dasatinib
• D. Change to ponatinib

[expand]The most appropriate second-line treatment for LP at this point in time is C. Change to dasatinib.

Rationale for Selection

1. Failure to Meet Establish Response Milestones: Achievement of a complete cytogenetic response (CCyR) within 12 months is considered the "gold standard" for managing chronic phase CML, as it is strongly associated with improved survival. Since LP has failed to achieve this milestone, her response is considered TKI-resistant, necessitating a switch in therapy.
2. Appropriate Sequence of Therapy: Clinical guidelines and expert recommendations state that if a second-generation TKI (such as bosutinib) is used in the first-line setting, the patient should be switched to an alternate second-generation TKI (like dasatinib or nilotinib) in the second-line setting.
3. Inappropriateness of Other Options:
   • Option A (Increase bosutinib to BID): There is no clinical evidence that increasing the dose of bosutinib to twice-daily provides an improved response in patients with chronic phase disease.
   • Option B (Change to high-dose imatinib): It is inappropriate to switch from a second-generation TKI to a first-generation TKI (imatinib) in this scenario. Furthermore, dose escalation of imatinib is unlikely to benefit patients who never achieved a cytogenetic response with a standard-dose TKI.
   • Option D (Change to ponatinib): Ponatinib is a third-generation TKI generally reserved for patients who have failed or are intolerant to at least two prior TKIs or for those who harbor the T315I mutation.

Pharmacist Clinical Note

Before initiating dasatinib, LP should undergo BCR::ABL1 kinase domain mutational analysis to ensure the new TKI is not predicted to be resistant to any emerging clones. Additionally, as LP is a 42-year-old female, the pharmacist should discuss her family planning goals, as achieving a deep and rapid molecular response with a second-generation TKI is a prerequisite for potentially attempting treatment-free remission later for pregnancy.

[/expand]

C. LP’s therapy is changed from bosutinib to dasatinib. Which of the following counseling points regarding any TKI therapy for CML would be important to stress to LP during your discussion with her?

• A. Food does not impact the effectiveness of TKIs.
• B. Adherence with TKI therapy is directly associated with outcome.
• C. TKIs should be taken once daily to maintain serum steady state concentration.
• D. TKIs will be discontinued if MMR is sustained for 2 years.

[expand] The most important counseling point to stress to LP from the provided options is B. Adherence with TKI therapy is directly associated with outcome.

Rationale for the Correct Answer (Option B)

According to the sources, patient adherence is the single most critical factor in the successful management of CML:

• Impact on Success: Adherence has been identified as the most important factor contributing to treatment success and the only independent predictor for achieving a complete molecular response on standard-dose therapy.
• Risk of Relapse: Studies (such as ADAGIO) demonstrate that patients with an adherence rate $\le$ 85% have a 27% probability of losing their complete cytogenetic response within two years, compared to only 1.5% for those with an adherence rate > 85%.
• Patient Perception: It is vital to explain the necessity of treatment even when the patient is asymptomatic, as nearly 30% of CML patients have been found to be non-adherent.

Why the Other Options are Incorrect

• Option A (Food): This is incorrect because food intake significantly impacts several TKIs. Nilotinib must be taken on an empty stomach (1 hour before or 2 hours after eating) because food can dangerously increase its absorption. Conversely, agents like imatinib and bosutinib should be taken with food to improve tolerability.
• Option C (Once Daily Dosing): This is incorrect because not all TKIs are dosed once daily. While imatinib, dasatinib, bosutinib, and ponatinib follow a once-daily schedule, nilotinib must be taken twice daily.
• Option D (Discontinuation): This is less appropriate than B because the criteria for Treatment-Free Remission (TFR) are much stricter than simply achieving MMR. To stop therapy, a patient must typically maintain a stable Deep Molecular Response (DMR or MR4, which is BCR::ABL1 ≤ 0.01%) for at least 2 years, not just a Major Molecular Response (MMR, which is ≤ 0.1%).

[/expand]

A 41-year-old male was recently diagnosed with chronic phase Philadelphia chromosome+ chronic myeloid leukemia (Ph+ CML). He has a prior history of gastroesophageal reflux disease (GERD), for which he takes pantoprazole 20 mg PO once daily. H₂ blockers and antacids do not work for him, and he has found that only pantoprazole adequately controls his GERD. He is to start an oral TKI treatment for CML, which one is the best agent to start for this patient?

1. Imatinib 400 mg daily (43%)
2. Dasatinib 100 mg daily (17%)
3. Nilotinib 300 mg twice a day (31%)
4. Bosutinib 500 mg daily (9%)

[expand] The best agent to start for this patient is Imatinib 400 mg daily.

Rationale for Selection

The primary factor determining the choice of therapy in this case is a significant drug-drug interaction involving the patient's medication for gastroesophageal reflux disease (GERD).

1. Interaction with Proton Pump Inhibitors (PPIs): The patient takes pantoprazole, a PPI, and explicitly states that H2 blockers and antacids are ineffective for him. Several tyrosine kinase inhibitors (TKIs) have pH-dependent absorption that is severely compromised by acid-reducing agents:

   • Dasatinib, Nilotinib, and Bosutinib all have specific recommendations to avoid acid reducers, including both H₂ antagonists and PPIs, because these agents can significantly decrease the TKI's absorption and clinical effectiveness.
   • While H₂ blockers can sometimes be managed by staggered dosing with certain TKIs, the sources strictly state that PPIs should be avoided altogether for dasatinib, nilotinib, and bosutinib.

2. Suitability of Imatinib:

   • Imatinib does not have a listed restriction regarding the use of PPIs or other acid-reducing agents in the provided pharmacologic tables.
   • It is an established first-generation TKI and remains a standard Category 1 recommendation for the first-line treatment of chronic phase CML (CP-CML).
   • The standard starting dose for CP-CML is 400 mg PO daily, and it is generally better tolerated when taken with food and a large glass of water.

Summary of Inappropriate Options

• Dasatinib: Contraindicated for concurrent use with PPIs like pantoprazole due to significantly reduced exposure.
• Nilotinib: Contraindicated for concurrent use with PPIs; additionally, nilotinib requires twice-daily dosing on an empty stomach, which may be more challenging for some patients.
• Bosutinib: Contraindicated for concurrent use with PPIs. (Note: While the query mentions 500 mg daily, the standard first-line dose for CP-CML is actually 400 mg PO daily).

[/expand]

TK is a 52-year-old female who presents with symptoms consistent with the diagnosis of chronic myelogenous leukemia (CML). As part of the initial diagnostic work-up, cytogenetic work-up has been ordered. Which of the following cytogenetic abnormality is most likely in TK?

1. translocation 9:22 (75%)
2. translocation 8:21 (12%)
3. translocation 4:14 (6%)
4. translocation 15:17 (7%)

[expand] The most likely cytogenetic abnormality in TK is translocation 9:22.

Rationale for the Abnormality

According to the sources, the diagnosis of Chronic Myeloid Leukemia (CML) is defined by a specific genetic hallmark:

• The Philadelphia Chromosome: CML results from an acquired reciprocal translocation between the long arms of chromosomes 9 and 22, which is designated as t(9;22).
• Juxtaposition of Genes: This translocation results in the juxtaposition of the Abelson murine leukemia (ABL1) gene from chromosome 9 and the breakpoint cluster region (BCR) gene from chromosome 22.
• BCR::ABL1 Fusion: The resulting BCR::ABL1 fusion protein acts as an oncogene, producing a constitutive proliferative signal that leads to continuous cell cycling and lack of apoptosis characteristic of the disease.
• Frequency in Patients: Up to 95% of CML patients possess the BCR::ABL1 fusion gene at the time of diagnosis.

Comparison with Other Options

While the sources mention other abnormalities such as trisomy 8 or trisomy 21, these are classified as additional cytogenetic abnormalities that develop as the leukemic clone expands and are typically associated with disease progression rather than the primary diagnosis.

• t(15;17): The hallmark of Acute Promyelocytic Leukemia (APL).
• t(8;21): A common translocation in Acute Myeloid Leukemia (AML).
• t(4;14): A high-risk cytogenetic marker found in Multiple Myeloma.

[/expand]

A 50-year-old female who has been on imatinib for 12 months for her CML diagnosis now has disease progression to blast phase CML. Her oncologist ordered a BCR-ABL mutation panel and found her to be T315I mutation positive. Which CML agent would be the best for this patient at this time?

1. Dasatinib
2. Bosutinib
3. Ponatinib
4. Omacetaxine

[expand] The best CML agent for this patient at this time is Ponatinib.

Rationale for Therapy Selection

• The T315I "Gatekeeper" Mutation: This specific mutation is characterized by the replacement of a wild-type threonine with a hydrophobic isoleucine in the ATP-binding pocket of the BCR::ABL1 protein. This change causes steric hindrance that prevents most tyrosine kinase inhibitors (TKIs) from binding effectively.
• Resistance Profile: The T315I mutation confers resistance to all first-generation (imatinib) and second-generation TKIs, including dasatinib and bosutinib. Consequently, switching to either of those agents would be clinically ineffective.
• Preferred Therapy: Ponatinib is a third-generation TKI specifically designed to be active against the T315I mutation. According to the sources, it is the preferred treatment for patients with a T315I mutation in any phase of the disease, including blast phase.
• Blast Phase Management: In the blast phase, the addition of a TKI to high-dose combination chemotherapy is recommended to improve outcomes. The choice of TKI must be guided by the mutation profile, making ponatinib the only appropriate choice among the listed TKIs.

Comparison with Other Options

• Dasatinib and Bosutinib: These agents are predicted to be resistant in the presence of the T315I mutation and are therefore inappropriate.
• Omacetaxine: While omacetaxine acts independently of BCR::ABL binding and has demonstrated activity against the T315I mutation, it is generally considered an alternative for patients who are resistant or intolerant to multiple TKIs. The sources explicitly designate ponatinib as the preferred agent for T315I-mutated disease.

Pharmacist Clinical Note

When initiating ponatinib, it is vital to monitor the patient for cardiovascular risks. The FDA has issued safety communications regarding life-threatening blood clots and vascular occlusion associated with this agent. The recommended starting dose is 45 mg PO daily, which may be reduced to 15 mg daily once the patient achieves an optimal molecular response (BCR::ABL1 ≤ 1%) to mitigate these risks.

[/expand]

Which agent is a first-line option for a newly diagnosed chronic phase CML in a 52-year-old woman with a WBC < 20,000/mm³?

1. Rituximab (27%)
2. Busulfan (7%)
3. Dasatinib (60%)
4. Interferon (6%)

[expand]Based on the provided sources, the correct first-line option for a newly diagnosed patient with chronic phase CML (CP-CML) is Dasatinib.

Rationale for Selection

• First-Line Recommendation: Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) that is established as an NCCN Guidelines® Category 1 recommendation for the first-line treatment of chronic phase CML.
• Broad Utility: It is considered a Category 1 preferred choice regardless of the patient's risk stratification (low, intermediate, or high risk).
• Clinical Performance: Trials such as DASISION demonstrated that dasatinib induces faster and deeper cytogenetic and molecular responses compared to the first-generation TKI, imatinib.
• Specific Patient Considerations: For younger patients (like this 52-year-old woman), second-generation TKIs like dasatinib may be preferred because they help achieve a rapid deep molecular response, which is a prerequisite for potentially attempting treatment-free remission in the future.

Why Other Options are Incorrect

• Rituximab: This is a monoclonal antibody used in the treatment of Chronic Lymphocytic Leukemia (CLL) and Hairy Cell Leukemia (HCL), but it has no role in the management of CML.
• Busulfan: This is a historical alkylating agent mentioned in the sources only in the context of being replaced by modern TKI therapy due to increased transplant-related complications.
• Interferon: This is considered a historical treatment for CML. While it was the standard of care before the introduction of TKIs, it currently has no standard role in practice except in very specific circumstances, such as managing CML during pregnancy.

[/expand]

If a patient presents with CNS symptoms such as severe headaches or stroke-like symptoms from leukocytosis, which type of leukemia would they most likely have if treated with hydroxyurea, allopurinol, and leukapheresis?

1. ALL (30%)
2. CLL (16%)
3. CML (44%)
4. Plasma cell leukemia (10%)

[expand]This is a classic leukostasis presentation, and the answer is: CML

Here's the reasoning:

Why CML fits perfectly:

The triad of treatments is the giveaway:

• Hydroxyurea — rapid cytoreduction to bring down an extremely high WBC count; it's a first-line bridge therapy in CML blast crisis or hyperleukocytosis
• Allopurinol — prevents tumor lysis syndrome (TLS), which is a major risk when rapidly lysing a massive myeloid burden
• Leukapheresis — mechanical removal of WBCs, used when counts are dangerously high (often >100–200 × 10⁹/L), exactly the range CML patients can reach

Why the others are less likely:

• ALL — can cause leukostasis, but lymphoblasts are less viscous than myeloblasts; hydroxyurea is not a primary agent in ALL management
• CLL — mature lymphocytes are small and deformable; leukostasis is rare even at very high counts because these cells don't plug microvasculature the way immature myeloid cells do; leukapheresis would be unusual
• Plasma cell leukemia — rare entity; plasma cells cause hyperviscosity via immunoglobulins (more like a myeloma picture), not leukostasis per se; treatment would differ significantly

The key pathophysiology: Immature myeloid blasts in CML (especially in accelerated/blast phase) are large, rigid, and adhesive — they physically occlude cerebral microvasculature, causing the CNS symptoms described. The higher the blast percentage and the higher the WBC (CML can present with WBC >300 × 10⁹/L), the greater the leukostasis risk.

[/expand]

Tyrosine kinase inhibitors (TKIs) have changed how we manage patients with chronic myelogenous leukemia (CML). Interferon-based therapy is no longer a standard of practice. Which of the following agents are appropriate to consider as a first-line treatment option for patients with CML?

1. Nilotinib, dasatinib, sorafenib
2. Sorafenib, sunitinib, imatinib
3. Imatinib, nilotinib, dasatinib
4. Imatinib, dasatinib, sunitinib 

[expand] The appropriate agents to consider as first-line treatment options for patients with Chronic Myeloid Leukemia (CML) are Imatinib, nilotinib, and dasatinib.

Rationale Based on the Sources

According to the provided sources, the selection of a tyrosine kinase inhibitor (TKI) for the initial treatment of chronic phase CML (CP-CML) is based on risk stratification and NCCN Guidelines®:

• Imatinib: This is a first-generation TKI and is established as a standard first-line option based on the landmark IRIS trial. It is considered an NCCN Category 1 recommendation for patients with low-risk disease and a recommended treatment option for intermediate- or high-risk disease.
• Dasatinib: This is a second-generation TKI and is a Category 1 preferred first-line choice for patients in all risk groups (low, intermediate, and high). Its first-line use was established by the DASISION trial.
• Nilotinib: This is another second-generation TKI and is also a Category 1 preferred first-line choice for patients in all risk categories. Its efficacy in the first-line setting was demonstrated in the ENESTnd trial.
• Bosutinib: Although not in your specific list of options, the sources also identify bosutinib as a second-generation TKI that is a Category 1 first-line option for CP-CML.

Why Other Agents are Inappropriate

The other options provided in your query include agents such as sorafenib and sunitinib. According to the sources, these agents are not used for the treatment of CML.

• Sorafenib and sunitinib are multi-kinase inhibitors, but they are not listed as available therapies for CML in the clinical pharmacology or treatment guidelines provided.
• The available TKIs for CML are specifically restricted to imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib.

[/expand]

A 62-year-old white female with suspected leukemia comes to the hospital.

Labs: WBC = 72.2, Hgb = 8.1, Hct = 24.7, Platelets = 333, Na = 142, K = 4.6, Cl = 106, CO₂ = 27, BUN = 25, Cr = 1.34, Phos = 5.8, Uric Acid = 12.9, LDH = 1933, Calcium = 9.1

Symptoms: Weight loss over the past 6 months with occasional fevers at night. She does not complain of fatigue or dyspnea on exertion.

Question: Which drug is preferred for maintenance treatment of this disease?

1. Tretinoin
2. Imatinib
3. Sunitinib
4. Interferon-alfa

[expand] Based on the clinical presentation and laboratory findings provided, the preferred drug for maintenance treatment is Imatinib.

Clinical Reasoning

1. Diagnosis: The patient's presentation—including significant leukocytosis (WBC 72.2 $k/\text{mm}^3$), anemia (Hgb 8.1 g/dL), and constitutional symptoms (weight loss and fevers)—is highly characteristic of Chronic Myeloid Leukemia (CML). The extremely high LDH (1933) and Uric Acid (12.9) are markers of high cell turnover and a high tumor burden, which can put the patient at risk for tumor lysis syndrome, a known complication in leukemias with high white blood cell counts.
2. Treatment Choice: Imatinib is a first-generation tyrosine kinase inhibitor (TKI) specifically designed to target the BCR::ABL1 fusion protein, which is the hallmark oncogene of CML.
3. Role in Maintenance: In the management of CML, the goal of therapy is to achieve and maintain hematologic, cytogenetic, and molecular remission. Continuous treatment with Imatinib has been established (through landmark studies like the IRIS trial) to induce durable responses and prevent disease progression.

Evaluation of Other Options

• Tretinoin: This agent is not listed as a treatment for CML or CLL in the sources; it is typically used for acute promyelocytic leukemia (APL).
• Sunitinib: This is a multi-kinase inhibitor that is not indicated for the treatment of CML in the provided guidelines.
• Interferon-alfa: While once a standard therapy, it is now considered a historical treatment for CML and is no longer preferred except in specific circumstances, such as pregnancy.

[/expand]

Cytogenetics were completed on the peripheral blood of a patient, which eventually demonstrated a t(9;22). What disease is typically seen with this chromosomal abnormality?

1. Chronic lymphocytic leukemia (15%)
2. Plasma cell leukemia (4%)
3. Acute promyelocytic leukemia (10%)
4. Chronic myelogenous leukemia (71%)

[expand]

The disease typically seen with the t(9;22) chromosomal abnormality is Chronic Myelogenous Leukemia (CML).

Rationale for the Abnormality

According to the sources, CML is uniquely defined by this specific hallmark genetic change:

• The Philadelphia Chromosome: The t(9;22) translocation is a reciprocal translocation between the long arms of chromosomes 9 and 22, which is termed the "Philadelphia chromosome" (Ph+).
• BCR::ABL1 Fusion Gene: This translocation results in the juxtaposition of the Abelson murine leukemia (ABL1) gene from chromosome 9 and the breakpoint cluster region (BCR) gene from chromosome 22.
• Oncogenic Driver: The resulting BCR::ABL1 fusion protein acts as an oncogene, producing a cytokine-independent, constitutive proliferative signal. This hyperactivity leads to continuous cell cycling, altered differentiation, and a loss of apoptosis, which are characteristic of the disease.
• Prevalence: Up to 95% of patients with CML possess this fusion gene at the time of diagnosis.

While other chronic leukemias like Chronic Lymphocytic Leukemia (CLL) involve cytogenetic abnormalities, the most common changes in those cases include deletion 13q, deletion 11q, trisomy 12, and deletion 17p; the t(9;22) translocation is not associated with CLL.

[/expand]

CD is a 59-year-old patient diagnosed with chronic phase CML. She was started on imatinib about 16 months ago. Today she has BCR-ABL FISH result confirming progression on imatinib. Her oncologist has decided to change her therapy to dasatinib. Which of the following is the most appropriate dosing of dasatinib?

1. 70 mg twice daily (10%)
2. 50 mg twice daily (6%)
3. 100 mg once daily (66%)
4. 140 mg once daily (19%)

[expand] The most appropriate dosing of dasatinib for CD is 100 mg once daily.

Rationale Based on the Sources

1. Disease Phase and Dosing: CD is diagnosed with chronic phase CML (CP-CML). According to the pharmacologic consideration tables in the sources, the established dosing for dasatinib in the chronic phase is 100 mg PO daily.
2. Management of Imatinib Resistance: The sources state that patients who do not respond to imatinib in the first-line setting should be switched to a second-generation TKI such as dasatinib. For patients with CP-CML who are imatinib-resistant or intolerant, the landmark CA180-034 study evaluated various dosing schedules and supported the efficacy of dasatinib in this setting.
3. Distinction from Advanced Phase Dosing: It is critical to distinguish between the doses used for different phases of the disease. While 100 mg once daily is the standard for chronic phase, the sources specify that a higher dose of 140 mg once daily is preferred for the accelerated phase (AP-CML).
4. Tolerability: Although historical dosing for dasatinib included twice-daily regimens (such as 70 mg BID), current standards favor once-daily dosing. The sources note that a twice-daily dosing schedule is actually a risk factor for the development of pleural effusions, a common adverse effect of dasatinib.

[/expand]

Which of the following statements is true concerning CML?

1. It is more common in children than adults (9%)
2. The presence of t(9;22) is diagnostic for CML (67%)
3. Bone marrow transplantation is not curative (9%)
4. Patients routinely have thrombocytopenia on diagnosis (15%)

[expand]The true statement concerning Chronic Myeloid Leukemia (CML) is that the presence of t(9;22) is diagnostic for CML.

Rationale Based on the Sources

• The Diagnostic Hallmark: CML is a unique malignancy characterized by a single genetic change that acts as the ultimate transforming event. This hallmark is a reciprocal translocation between the long arms of chromosomes 9 and 22, designated as t(9;22). In clinical practice, as seen in the patient cases provided, a cytogenetic analysis positive for t(9;22) is used to confirm the diagnosis of chronic phase CML.
• The Philadelphia Chromosome: This translocation results in the formation of the Philadelphia chromosome (Ph+) and the BCR::ABL1 fusion protein. This protein produces a constitutive, cytokine-independent proliferative signal that drives the continuous cell cycling and lack of apoptosis seen in the disease.

Why the Other Statements are False

• Commonality in Children vs. Adults: While the sources focus on CLL as a disease of the elderly (median age of 72), CML is also managed as a chronic disease in adults, with the risk of death from co-existing conditions often being greater than that of CML itself. The sources do not support the claim that it is more common in children.
• Bone Marrow Transplantation: The sources discuss allogeneic hematopoietic stem cell transplantation (HSCT) as a recommended treatment for patients in advanced phases or those who fail tyrosine kinase inhibitor (TKI) therapy. Historically, CML was regarded as incurable until the introduction of modern therapies, which include transplantation and TKIs.
• Platelet Counts at Diagnosis: Patients do not routinely have thrombocytopenia (low platelets) at diagnosis. In fact, the patient cases provided (PK and LP) both presented with normal platelet counts of 197,000 cells/mm³. Furthermore, the Sokal and Hasford risk scores specifically use platelet count as a variable, noting that counts can be high or low depending on the individual case.

[/expand]

The treatment of choice for CML blast crises is:

• Imatinib 800 mg once daily
• Dasatinib 70 mg twice daily
• Cytarabine plus interferon
• Allogeneic stem cell transplantation

[expand] Based on the provided sources, the treatment of choice for CML blast crisis among the given options is allogeneic stem cell transplantation.

The rationale, as outlined in the sources, is as follows:

• Curative Potential and Recommendations: Evaluation for allogeneic hematopoietic stem cell transplantation (HSCT) is recommended for all patients who present with or progress to blast crisis (BP-CML). While initial therapy focuses on using a TKI in combination with high-dose induction chemotherapy to reduce disease burden, the ultimate goal is to bridge the patient to a transplant once a second chronic phase is achieved.
• Goal of Therapy: The primary objective in blast crisis is to induce the patient back into a chronic phase, as this transformation effectively represents an acute leukemia with a median survival of only 6–12 months without definitive intervention.
• Role of TKIs: While TKIs like imatinib, dasatinib, nilotinib, and bosutinib are used in the blast phase, they are typically administered in combination with high-dose chemotherapy (AML- or ALL-type) rather than as monotherapy to improve response rates before proceeding to transplant.

Evaluation of Other Options

• Imatinib 800 mg once daily: This dose is specifically listed as a recommended option for the accelerated phase (AP-CML), but for blast crisis, a second- or third-generation TKI is generally preferred over imatinib.
• Dasatinib 70 mg twice daily: This is a historical dosing schedule. Current guidelines for advanced phase disease prefer dasatinib 140 mg once daily, as twice-daily dosing is associated with a higher risk of adverse events like pleural effusions.
• Cytarabine plus interferon: This is a historical regimen evaluated in the IRIS trial; it has been replaced by TKI-based therapy and is no longer a standard of practice for CML.

[/expand]

12. Treatment of patient with T315I mutation is:

1. Imatinib 800 mg
2. Nilotinib 400 mg bd
3. Dasatinib 70 mg bd
4. Allogenic stem cell transplantation

[expand] Based on the resistance profile of the T315I mutation described in the sources, the correct treatment from the provided list is Allogeneic stem cell transplantation.

Rationale Based on the Sources

• The "Gatekeeper" Mutation: The T315I mutation is characterized by a conformational change in the ATP-binding pocket of the BCR::ABL1 protein that causes steric hindrance, preventing the binding of most tyrosine kinase inhibitors (TKIs).
• Widespread Resistance: According to the mutation sensitivity tables in the sources, the T315I mutation specifically predicts resistance to imatinib, dasatinib, nilotinib, and bosutinib. Therefore, the first three options listed (Imatinib 800 mg, Nilotinib 400 mg bd, and Dasatinib 70 mg bd) would be clinically ineffective for a patient with this mutation.
• Role of Transplantation: The sources state that allogeneic hematopoietic stem cell transplantation (HSCT) should be considered for patients with TKI-resistant disease. Furthermore, performing mutational analysis is specifically recommended to identify which patients—such as those with the high-risk T315I mutation—are candidates for HSCT.
• Drug Alternatives (Not in the Options): While ponatinib is the preferred pharmacologic treatment for patients with a T315I mutation in any phase, followed by agents like asciminib and omacetaxine, none of these were provided as choices in your list.

In the absence of the specific third-generation TKIs designed to overcome this resistance, allogeneic stem cell transplantation remains the standard curative approach for managing a patient with the T315I mutation who has failed or cannot take active TKI therapy.

[/expand]

13. True about CML are, all except:

• a. Basophilia is universal
• b. Eosinophilia is seen in about 90% of cases
• c. Fusion protein p190 is most common, though p210 is also seen in some cases.
• d. All of the above

[expand] Based on the provided sources, the statement that is NOT true (the "except") is:

c. Fusion protein p190 is most common, though p210 is also seen in some cases.

Rationale for the Incorrect Statement (Option C)

According to the sources, the relationship between these fusion proteins is exactly the opposite of what is stated in this option:

• p210 is the Hallmark: The sources explicitly state that the most common form of the BCR::ABL1 fusion protein in CML is known as p210BCR::ABL1.
• Common Form: Another source reinforces this by identifying p210 as the "common form" of the active tyrosine kinase region of ABL1.
• Diagnostic Significance: The presence of this specific fusion protein is a result of the t(9;22) translocation, which acts as the ultimate transforming event for the disease.

Context for Other Options

While the provided source excerpts do not provide specific percentage frequencies for basophilia or eosinophilia, they confirm these are standard clinical features of CML:

• Risk Stratification: The Hasford model, a prognostic scoring system for CML, specifically uses the percentages of eosinophils and basophils in the peripheral blood as key variables.
• Cell Lineage: CML is described as a myeloproliferative expansion where the "Blood Cancer Family Tree" shows CML arising from the myeloid stem cell line that produces granulocytes, including basophils and eosinophils.
• Historical Knowledge (Outside Sources): In clinical practice, basophilia is considered a nearly universal finding in CML, and eosinophilia is present in the vast majority (often cited as ~90%) of cases.

Because the sources definitively identify p210 (not p190) as the most common fusion protein, Option C is the false statement.

[/expand]

14. The Sokal score for CML include, all except:

• a. Spleen size
• b. Blasts percent
• c. Basophil percent
• d. Age
• e. Platelet count

[expand] Based on the sources, the Sokal score for CML includes all the listed variables except c. Basophil percent.

Rationale Based on the Sources

According to multiple sections in the provided material, the variables used to calculate the Sokal score and other prognostic models are specifically defined:

• Sokal Score Components: The sources explicitly state that the Sokal score is based on four clinical variables: patient age, spleen size, platelet count, and percentage of blasts in the peripheral blood. A detailed mathematical formula provided in the sources confirms these four factors are the only inputs for calculating the Sokal hazard ratio.
• Basophil Percent: The sources clarify that while the Hasford model (also known as the EuroSCORE) uses the same four variables as the Sokal score, it additionally includes eosinophils and basophils in the peripheral blood to stratify patient risk.
• ELTS Score Comparison: The more contemporary ELTS score also utilizes age, spleen size, platelet count, and blast percentage, but it weights these criteria differently than the Sokal score (placing less emphasis on age) and was derived from data on patients treated with tyrosine kinase inhibitors (TKIs).

[/expand]

15. Imatinib is capable of inhibiting:

1. Tyrosine kinase
2. c-kit
3. Platelet-derived growth factor receptor
4. All of the above

[expand] Answer: d. All of the above 

Imatinib inhibits tyrosine kinases, c-kit and platelet-derived growth factor receptor, and can be used in treating malignancies in which these are overexpressed

[/expand]

16. Pregnant patient with CML should be treated with:

• a. Imatinib
• b. Nilotinib
• c. Dasatinib
• d. Interferon

[expand] A pregnant patient with CML should be treated with d. Interferon.

Rationale Based on the Sources

According to the provided sources, the role of interferon in the modern era of CML management is very limited, with one specific clinical exception:

• Standard for Pregnancy: The sources explicitly state that while interferon alfa is a historical treatment for CML, it currently has "no standard role in current practice except in the treatment of CML during pregnancy".
• Avoidance of TKIs: The management of young women with CML often prioritizes achieving a rapid and deep molecular response (DMR) with tyrosine kinase inhibitors (TKIs) so that they can eventually discontinue therapy for family planning or fertility purposes. This underscores that TKIs (Options a, b, and c) are generally not the preferred agents to use during a pregnancy.

[/expand]

17. Hasford system is related to:

• a. Hodgkin’s disease
• b. NHL
• c. CML
• d. Cutaneous lymphoma

[expand] The Hasford system (also known as the Hasford model or EuroSCORE) is related to c. CML (Chronic Myeloid Leukemia).

Rationale Based on the Sources

According to the source material, the Hasford system is a prognostic risk stratification tool used specifically for patients with Chronic Myeloid Leukemia:

• Function: It is an arithmetically derived system used at baseline to estimate survival risk.
• Variables: It utilizes the same clinical variables as the Sokal score—patient age, spleen size, platelet count, and percentage of blasts in the peripheral blood—but additionally includes the percentages of eosinophils and basophils.
• Risk Groups: Based on these factors, patients are stratified into low-, intermediate-, or high-risk groups.
• Clinical Use: While contemporary references often advocate for the more modern ELTS score (which is based on data from patients treated with TKIs), the Hasford and Sokal scores remain established historical systems for CML initial treatment selection and clinical trial stratification.

[/expand]

18. The following are common side effects of Imatinib, except:

• a. Skin rashes
• b. Leg edema
• c. Diarrhea
• d. Renal dysfunction

[expand] Based on the provided sources, the common side effects of Imatinib include skin rashes, fluid retention (edema), and diarrhea, while renal dysfunction is not listed as a common side effect.

Rationale Based on the Sources

• Skin Rashes (Option A): The sources explicitly list rash as a unique toxicity associated with Imatinib. It is common enough that management strategies, such as topical or systemic steroids, are provided.
• Leg Edema (Option B): Imatinib is frequently associated with fluid retention, which can manifest as edema (specifically periorbital edema), pleural effusion, or ascites. Management often requires loop diuretics and a decrease in sodium intake.
• Diarrhea (Option C): While Bosutinib is the TKI most famously associated with diarrhea, the sources indicate that diarrhea is also a side effect of Imatinib. For example, the LAST study found that patients who discontinued their TKIs (including Imatinib) reported clinically meaningful improvements in diarrhea, confirming it was a drug-induced symptom.
• Renal Dysfunction (Option D - The Correct "Except"): According to the sources, renal dysfunction is not a side effect caused by Imatinib. Instead, it is a pre-existing condition that must be monitored; the pharmacologic tables specify that dose reductions are required for patients who have baseline renal impairment.

[/expand]

19. In CML, BCR ABL transcript seen commonly is:

• a. p230
• b. p190
• c. p210
• d. p240

[expand] In Chronic Myeloid Leukemia (CML), the most commonly seen BCR::ABL1 transcript is c. p210.

Rationale Based on the Sources

According to the provided sources, the BCR::ABL1 fusion protein resulting from the t(9;22) translocation comes in various forms, but one is predominant in CML:

• Most Common Form: The sources explicitly state that "the most common form is known as p210BCR::ABL1".
• Protein Function: This p210 form contains the active tyrosine kinase region of ABL1. While the normal ABL1 tyrosine kinase carefully regulates cell proliferation and survival, the p210 fusion protein produces a constitutive, cytokine-independent proliferative signal.
• Disease Mechanism: This hyperactivity leads to the hallmark features of CML, including continuous cell cycling, altered differentiation, and a loss of apoptosis.

While other transcripts like p190 can occur, the sources consistently identify p210 as the hallmark transcript for the vast majority of CML cases.

[/expand]

20. In CML Philadelphia chromosome is present in:

• a. Myeloid cell
• b. B-lymphocytes
• c. T-lymphocytes
• d. All of the above

[expand]In Chronic Myeloid Leukemia (CML), the Philadelphia chromosome is present in d. All of the above.

Rationale Based on the Sources

1. Origin in Hematopoietic Stem Cells: The sources explicitly state that CML results from an acquired mutation (the t(9;22) translocation) that affects hematopoietic stem cells (HSCs).
2. Lineage Ancestry: According to the "Blood Cancer Family Tree" provided in the sources, the hematopoietic stem cell is the common ancestor for all blood lineages. This includes:
   • Myeloid cells (granulocytes, red blood cells, and platelets).
   • Lymphoid cells (B-lymphocytes, T-lymphocytes, and Natural Killer cells).
3. Presence in Lymphoid Lineages: Because the translocation occurs at the level of the multipotent stem cell, the resulting Philadelphia chromosome (Ph+) is passed down to all its progeny. This is clinically evidenced by the lymphoid variant of blast crisis (BP-CML), where the disease transforms into a Ph+ acute leukemia that behaves like Acute Lymphoblastic Leukemia (ALL).
4. Treatment Implications: The sources note that in lymphoid-type blast crisis, the leukemia cells involve the lymphoid lineage, requiring induction regimens similar to those used for ALL.

Because the Ph+ mutation originates in the parent cell (HSC) of both the myeloid and lymphoid branches, it can be detected in myeloid cells, B-lymphocytes, and T-lymphocytes.

[/expand]

21. Imatinib acts by:

• a. Phosphorylation
• b. Dephosphorylation
• c. Demethylation
• d. Methylation

[expand] Answer: b. Dephosphorylation

• Imatinib is an ABL1 tyrosine kinase inhibitor. It binds to and occupies the ATP-binding pocket of the ABL1 kinase component of the BCR-ABL1 protein, thereby blocking the capacity of the enzyme to phosphorylate downstream effector molecules, thereby blocking the manifestations of CML.
• So imatinib acts as a synthetic ATP mimic which fits in the pocket for ATP in the BCR-ABL molecule thereby displacing it and preventing the ATP-mediated phosphorylation. The drug rapidly reverses the clinical and haematological abnormalities and induces major cytogenetic responses in over 80% of previously untreated CML chronic-phase patients.

[/expand]

22. All are the side effects of Imatinib therapy, except:

• a. Edema
• b. Hair loss
• c. Rashes
• d. Bone pains

[expand]Based on the provided sources, the side effect that is NOT associated with Imatinib therapy among the choices is b. Hair loss.

Rationale Based on the Sources

The sources explicitly identify the following as common or unique toxicities of Imatinib:

• Edema (Option A): Fluid retention is a hallmark side effect of Imatinib. It manifests as periorbital edema (swelling around the eyes), but can also include more serious forms such as pleural effusion, pericardial effusion, and ascites.
• Rashes (Option C): Rash is listed as a unique toxicity for Imatinib. It is common enough that management strategies, including the use of topical or systemic steroids, are provided in the clinical guidelines.
• Bone pains / Musculoskeletal pain (Option D): Imatinib is frequently associated with musculoskeletal pain. Additionally, the sources note that Imatinib can cause hypophosphatemia and associated changes in bone and mineral metabolism, requiring clinicians to monitor bone health during ongoing treatment.

Why Hair Loss is the Exception

There is no mention of hair loss (alopecia) in the comprehensive toxicity tables or clinical management sections for Imatinib in the provided sources. While other gastrointestinal effects like nausea and diarrhea are highlighted, hair loss is not listed as a side effect for this specific agent.

[/expand]

SN is a 55-year-old woman who was diagnosed with medium risk CML. She was on Dasatinib 100 mg daily 3 months ago & underwent assessment. Her TLC=8,000/mm³, PLTs=200,000/mm³, BCR-ABL1=20% & 65% Ph+ metaphases of baseline value. Which of the following is correct?

• A. We should start different TKI immediately
• B. Continue on Dasatinib 400 mg and monitor response 3 months later & if she lost CHR, BCR-ABL >10% or Ph+ metaphases >35%, start a different TKI
• C. CCYR should be achieved at 6 months maximum
• D. Continue on Dasatinib 400 mg and monitor response 3 months later & if BCR-ABL>10% or Ph+ metaphases>65%, start a different TKI
• E. CCYR should be achieved at 12 months maximum

[expand] Based on the clinical assessment and the provided sources, the correct statement is E. CCYR should be achieved at 12 months maximum.

Clinical Evaluation of SN (at 3 Months)

• Hematologic Response: SN's TLC (8,000/mm³) and Platelets (200,000/mm³) are within the normal range, confirming she has achieved a Complete Hematologic Response (CHR), which is expected by the 3-month mark.
• Molecular/Cytogenetic Response: Her BCR::ABL1 level is 20%, and she has 65% Ph+ metaphases.
  • The goal for Early Molecular Response (EMR) at 3 months is BCR::ABL1 $\le$ 10%.
  • Since her level is $>10%$, both the NCCN and European LeukemiaNet (ELN) classify this result as "Yellow" (NCCN) or a "Warning" (ELN).

Rationale for the Correct Option (E)

The sources repeatedly emphasize that achieving a Complete Cytogenetic Response (CCyR)—defined as 0% Ph+ metaphases—within 12 months is the "gold standard" of therapy. Meeting this specific milestone is critical because it is directly associated with improved long-term survival.

Evaluation of Other Options

• A. Start different TKI immediately: This is incorrect. A result of $>10%$ at 3 months is a "Warning," not an absolute treatment failure. Guidelines suggest evaluating adherence and drug interactions or performing mutational analysis before deciding to switch.
• B & D. Continue on Dasatinib 400 mg: These options are pharmacologically incorrect. The established dose for dasatinib in the chronic phase is 100 mg daily. A dose of 400 mg is standard for imatinib, but not for dasatinib. Furthermore, increasing the dose of a second-generation TKI for an inadequate response is not supported by the sources.
• C. CCYR should be achieved at 6 months maximum: While achievement of CCyR can happen at 6 months, the sources identify 12 months as the definitive deadline to meet the "gold standard" milestone for survival.

[/expand]